Retraction: Butyrate attenuates lipopolysaccharide-induced inflammation in intestinal cells and Crohn's mucosa through modulation of antioxidant defense machinery (PLoS One (2012) 7:3 (e32841) DOI: 10.1371/journal.pone.0032841);Butyrate attenuates lipopolysaccharide-induced inflammation in intestinal cells and Crohn's mucosa through modulation of antioxidant defense machinery

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Russo, Ilaria ^a   Luciani, Alessandro ^a   de Cicco, Paola ^a   Troncone, Edoardo ^a   Ciacci, Carolina ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; CYCLOOXYGENASE 2; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GLUTATHIONE TRANSFERASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; REACTIVE OXYGEN METABOLITE; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; ANTIOXIDANT; BUTYRIC ACID DERIVATIVE; GLUTATHIONE S-TRANSFERASE ALPHA; GLUTATHIONE TRANSFERASE; ISOENZYME; LIPOPOLYSACCHARIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLON MUCOSA; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE RELEASE; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM CELL; LAMINA PROPRIA; MONONUCLEAR CELL; MUCOSA INFLAMMATION; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ADOLESCENT; CATALYSIS; CELL LINE; DRUG EFFECT; ENZYME ACTIVATION; GENE EXPRESSION; GENETICS; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY;

ESCHERICHIA COLI;

ADOLESCENT; ADULT; ANTIOXIDANTS; BUTYRATES; CATALYSIS; CELL LINE; CROHN DISEASE; ENZYME ACTIVATION; GENE EXPRESSION; GLUTATHIONE TRANSFERASE; HUMANS; INTESTINAL MUCOSA; ISOENZYMES; LIPOPOLYSACCHARIDES; NF-KAPPA B; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; YOUNG ADULT;

EID: 84857833863     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0224849     Document Type: Erratum

References (56)

1. Hörmannsperger G, Haller D, (2010) Molecular crosstalk of probiotic bacteria with the intestinal immune system: Clinical relevance in the context of inflammatory bowel disease. Intern J of Medical Microbiol 300: 63-73.
2. Sekirov I, Russell SL, Antunes CM, Finlay BB, (2010) Gut Microbiota in Health and Disease. Physiol Rev 90: 859-904.
3. Thompson-Chagoyan OC, Maldonado A, Gilc Ã, (2005) Aetiology of inflammatory bowel disease (IBD). Role of intestinal microbiota and gut-associated lymphoid tissue immune response. Clinical Nutrition 24: 339-52.
4. Roy MA, (1997) Inflammatory bowel disease. Surgical Clinics of North America 77: 1419-1431.
5. Kruidenier L, Kuiper I, Lamers CB, Verspaget HW, (2003) Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants. J Pathol 201: 28-36.
6. Kruidenier L, Verspaget HW, (2002) Oxidative stress as a pathogenic factor in inflammatory bowel disease-radicals or ridiculous? Aliment Pharmacol Ther 16: 1997-2015.
7. Kruidenier L, Kuiper I, Van Duijn W, Mieremet-Ooms MA, van Hogezand RA, et al. (2003) Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease. J Pathol 201: 17-27.
8. Rezaie A, Parker RD, Abdollahi M, (2007) Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci 52: 2015-2021.
9. Gloire G, Legrand-Poels S, Piette J, (2006) NF-kappa B activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 72: 1493-150510.
10. Dignass AU, Baumgart DC, Sturm A, (2004) The aetiopathogenesis of inflammatory bowel disease immunology and repair mechanisms. Alimentary Pharmacology & Therapeutics 20: 9-17.
11. Hörmannsperger G, Clavel T, Hoffmann M, Reiff C, Kelly D, et al. (2010) Posttranslational Inhibition of Proinflammatory Chemokine Secretion in Intestinal Epithelial Cells: Implications for Specific IBD Indications. Journal of Clinical Gastroenterology 44: S10-S15.
12. van Langen L, Mirjam AC, Prajapati V, Levinus DA, (2008) Probiotics and Prebiotics as Functional Ingredients in Inflammatory. Bowel Disease Nutrition Today 43: 235-24213.
13. Tuohy KM, Probert HM, Smejkal CW, Gibson GR, (2003) Using probiotics and prebiotics to improve gut health. Drug Discovery Today 8: 692-700.
14. Daly K, Shirazi-Beechey SP, (2006) Microarray analysis of butyrate regulated genes in colonic epithelial cells. DNA Cell Biol 25: 49-62.
15. Peng L, Li ZR, Green RS, Holzman IR, Lin J, (2009) Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr 139: 1619-1625.
16. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, et al. (2008) Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 27: 104-119.
17. Segain JP, Raingeard de la Bletiere D, Bourreille A, Leray V, Chen CH, et al. (2000) Butyrate inhibits inflammatory responses through NF-kappa B inhibition: implications for Crohn's disease. Gut 47: 397-403.
18. Kinoshita M, Suzuki Y, Saito Y, (2000) Butyrate reduces colonic paracellular permeability by enhancing PPAR gamma activation. Biochem Biophys Res Commun 293: 827-831.
19. Lührs H, Gerke T, Müller JG, Melcher R, Schauber J, et al. (2002) Butyrate inhibits NF-kappa B activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol 37: 458-466.
20. Scheppach W, Sommer H, Kirchner T, Paganelli GM, Bartram P, et al. (1992) Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology 103: 51-66.
21. Harig JM, Soergel KH, Komorowski RA, Wood CM, et al. (1989) Treatment of diversion colitis with short-chain-fatty acid irrigation. N Engl J Med 320: 23-28.
22. Guillemot F, Colombel JF, Neut C, Verplanck N, Le-comte M, et al. (1991) Treatment of diversion colitis by short-chain fatty acids. Prospective and double-blind study. Dis Colon Rectum 34: 861-864.
23. Koutroubakis IE, Malliaraki N, Dimoulios P, Karmiris K, Castanas E, et al. (2004) Decreased Total and Corrected Antioxidant Capacity in Patients withInflammatory Bowel Disease. Dig Dis Sci 49: 1433-1437.
24. Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, et al. (2010) The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. European Crohn's and Colitis Organisation (ECCO). J Crohns Colitis 4: 7-27.
25. Raia V, Maiuri L, Ciacci C, Ricciardelli I, Vacca L, et al. (2005) Inhibition of p38 mitogen activated protein kinase controls airway inflammation in cystic fibrosis. Thorax 60: 773-780.
26. Luciani A, Villella VR, Esposito S, Brunetti-Pierri N, Medina DL, et al. (2011) Cystic fibrosis: a disorder with defective autophagy. Autophagy 7: 104-106.
27. Luciani A, Villella VR, Vasaturo A, Giardino I, Pettoello-Mantovani M, et al. (2010) Lysosomal accumulation of gliadin p31-43 peptide induces oxidative stress and tissue transglutaminase-mediated PPARgamma down-regulation in intestinal epithelial cells and coeliac mucosa. Gut 311-319.
28. Maiuri L, Ciacci C, Ricciardelli I, Vacca L, Raia V, et al. (2003) Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease. Lancet 362: 3-37.
29. Hissin PJ, Hilf R, (1976) A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 74: 214-226.
30. Luciani A, Villella VR, Vasaturo A, Giardino I, Raia V, et al. (2009) SUMOylation of tissue transglutaminase as link between oxidative stress and inflammation. J Immunol 183: 2775-2784.
31. El Bekay R, Alvarez M, Monteseirín J, Alba G, Chacón P, et al. (2003) Oxidative stress is a critical mediator of the angiotensin II signal in human neutrophils: involvement of mitogen-activated protein kinase, calcineurin, and the transcription factor NF-k B. Blood 102: 662-669.
32. Barone MV, Gimigliano A, Castoria G, Paolella G, Maurano F, et al. (2007) Growth factor-like activity of gliadin, and alimentary protein: implications for coeliac disease. Gut 56: 480-488.
33. Maiuri L, Luciani A, Giardino I, Raia V, Villella VR, et al. (2008) Tissue Transglutaminase activation modulates inflammation in Cystic Fibrosis via PPAR-γ downregulation. J Immunol 180: 7697e705.
34. Thibault R, Blachier F, Darcy-Vrillon B, de Coppet P, Bourreille A, et al. (2010) Butyrate utilization by the colonic mucosa in inflammatory bowel diseases: a transport deficiency. Inflamm Bowel Dis 16: 684-695.
35. Roediger WE, (1980) The colonic epithelium in ulcerative colitis: an energy-deficiency disease? Lancet 2: 712-715.
36. Di Sabatino A, Cazzola P, Ciccocioppo R, Morera R, Biancheri P, et al. (2007) Efficacy of butyrate in the treatment of mild to moderate Crohn's disease. Digestive and Liver Disease 1: 31-35.
37. Duffy MM, Regan MC, Ravichandran P, O'Keane C, Harrington MG, et al. (1998) Mucosal metabolism in ulcerative colitis and crohn's disease. Diseases of the Colon & Rectum 41: 1399-1405.
38. Ahmada MS, Krishnana S, Ramakrishna BS, Pulimooda AB, et al. (2000) Butyrate and glucose metabolism by colonocytes in experimental colitis in mice. Gut 46: 493-499.
39. Roediger WE, (1982) Utilization of nutrients by isolated epithelial cells of the rat colon. Gastroenterology 83: 424-429.
40. Jørgensen J, Mortensen PB, (2001) Substrate utilization by intestinal mucosal tissue strips from patients with inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 281: G405-11.
41. Finnie IA, Taylor BA, Rhodes JM, (1993) Ileal and colonic epithelial metabolism in quiescent ulcerative colitis: increased glutamine metabolism in distal colon but no defect in butyrate metabolism. Gut 34: 1552-1558.
42. Chapman MA, Grahn MF, Boyle MA, Hutton M, Rogers J, et al. (1994) Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis. Gut 35: 73-76.
43. Moreau NM, Champ MM, Goupry SM, Le Bizec BJ, Krempf M, et al. (2004) Resistant starch modulates in vivo colonic butyrate uptake and its oxidation in rats with dextran sulfate sodium-induced colitis. J Nutr 134: 493-500.
44. Zambell KL, Fitch MD, Fleming SE, (2003) Acetate and butyrate are the major substrates for de novo lipogenesis in rat colonic epithelial cells. J Nutr 133: 3509-3515.
45. Cuff M, Dyer J, Jones M, Shirazi-Beechey S, (2005) The human colonic monocarboxylate transporter Isoform 1: its potential importance to colonic tissue homeostasis. Gastroenterology 128: 676-686.
46. Thibault R, De Coppet P, Daly K, Bourreille A, Cuff M, et al. (2007) Down-regulation of the monocarboxylate transporter 1 is involved in butyrate deficiency during intestinal inflammation. Gastroenterology 133: 1916-1927.
47. Bowling AC, Beal MF, (1995) Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sciences 56: 1151-1171.
48. van der Vliet A, Bast A, (1992) Role of reactive oxygen species in intestinal diseases. Free Radic Biol Med 12: 499-513.
49. Iantomasi T, Marraccini P, Favilli F, Vincenzini MT, Ferretti P, et al. (1994) Glutathione metabolism in Crohn's disease. Biochem Med Metab Biol 53: 87-91.
50. Lih-Brody L, Powell SR, Collier KP, Reddy GM, Cerchia R, et al. (1996) Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig Dis Sci 41: 2078-2086.
51. Hamer HM, Jonkers DM, Bast A, Vanhoutvin SA, Fischer MA, et al. (2009) Butyrate modulates oxidative stress in the colonic mucosa of healthy humans. Clin Nutr 28: 88-93.
52. Butzner JD, Parmar R, Bell CJ, Dalal V, (1996) Butyrate enema therapy stimulates mucosal repair in experimental colitis in the rat. Gut 38: 568-73.
53. Zeng H, Briske-Anderson M, (2005) Prolonged butyrate treatment inhibits the migration and invasion potential of HT1080 tumor cells. J Nutr 135: 291-295.
54. Habig WH, Pabst MJ, Jakoby WB, (1974) Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 249: 7130-7139.
55. Marchesi JR, Holmes E, Khan F, Kochhar S, Scanlan P, et al. (2007) Rapid and non-invasive metabonomic characterization of inflammatory bowel disease. J Proteome Res 6: 546-551.
56. Takada Y, Mukhopadhyay A, Kundu GC, Mahabeleshwar GH, Singh S, et al. (2003) Hydrogen peroxide activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha and serine phosphorylation of p65: evidence for the involvement of I kappa B alpha kinase and Syk protein-tyrosine kinase. J Biol Chem 278: 24233-2424.